KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...

Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer Following investigational new ...

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ...

PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...

Prostate cancer highlights from the American Urological Association 2025 meeting include quality-of-life results from the phase 3 PSMAfore study, findings on androgen deprivation therapy (ADT) with or ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...